Date of Award
Master of Science (MS)
Introduction. Radiolabeled molecules for use in disease detection and targeted treatment are a mainstay of patient management. The majority of radiopharmaceuticals deployed to date undergo a single radioactive transition (decay) to reach a stable ground state. Complex emitters, which produce a series of daughter radionuclides, are emerging as novel radiopharmaceuticals, and there is a need for the proper validation of content and purity using common quality control instrumentation. Hypothesis. There is a need for proper characterization of complex emitters for more accurate quality control on readily available equipment. Here, we demonstrate the novel characterization of Th-227 and Ra-223 using a solid-state semiconductor alpha detector, a gamma counter, and a radio-TLC scanner, three widely accessible technologies. Results. In this work, we validate the ability of the alpha particle spectral imaging camera and the gamma counter to distinguish Th-227 from Ra-223, allowing for fast, qualitative, and quantitative determination of radionucleic purity. We also assess the utility and accuracy of the Bioscan radio-TLC to measure these radionuclides under different high voltage settings. Finally, we validate our results and demonstrate the practical applications of this work through evaluation of a Th-227-labeled antibody construct. Conclusion. Our results develop a novel quality control protocol for Th-227 and Ra-223 on three different, readily available instruments. These results can be applied to both research and clinical settings as new alpha particle therapies are developed for cancer treatment.
Diane Abou Michael Nickles
Available for download on Wednesday, June 29, 2022